Home » Topics » BioWorld Science

BioWorld Science
RSS

FGF21 switches sides in pancreatitis

Jan. 13, 2020

Curadev Pharma synthesizes new STING agonists

Jan. 13, 2020

New tankyrase 1/2 inhibitors patented by Forschungsverbund Berlin and collaborators

Jan. 13, 2020

Heptares Therapeutics describes new muscarinic acetylcholine M1 and/or M4 receptor agonists

Jan. 13, 2020

Mutations in TTC29 gene linked to male infertility

Jan. 13, 2020

Daiichi Sankyo presents a new orally potent analgesic, DS-54360155

Jan. 13, 2020

Novel ATX inhibitor shows promise as IOP-lowering therapy in vivo

Jan. 13, 2020

Positive results from pivotal phase II study of loncastuximab tesirine in DLBCL

Jan. 13, 2020

Nomacopan achieves primary endpoint at interim analysis of phase III CAPSTONE study

Jan. 13, 2020

Moderna begins phase II study of CMV vaccine mRNA-1647

Jan. 13, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...